CD274 and neoplasm: Tumor cells, including LL/2 and CT26, exhibit high PD-L1 levels, 67.1% in LL/2 and 91.2% in CT26 (Fig. 5A), which present opposite responses to αPD-L1 immunotherapy, immunotherapy-sensitive in CT26 and immunotherapy-resistant in LL/2 (Fig. 7C).